ERBB2 and breast cancer: In terms of NAC efficacy among patients with HER2-negative breast cancer in the Chinese population, our study found that the pCR rate of HER2-low was significantly lower than that of HER2-zero (16.4% vs. 24.0%, p = 0.003), but this was only limited to the univariate analysis.